|
Androgen Deprivation Monotherapy for PCa
(February 2007)
Abstract 4610, ASCO 2006, by Beer, Graff, et al. reports a 5-year 66%
overall survival (OS) and cancer specific survival (CSS) of 91% in 276 men
with localized cancer treated within 6 months after diagnosis with
androgen deprivation only. The median age at diagnosis was 75 (50-88) and
the median follow-up was 7.6 years. The Gleason score >7 was the
only independent predictor CSS (p=0.040); and having a PSA > 20
approached significance as an adverse predictor «
Back to Article List |
